Logo Image

Jose Pacheco, MD

Articles by Jose Pacheco, MD

81 A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients Who Have Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression

ByDena Westphalen,Sarah Goldberg, MD, MPH ,Muhammad Rizwan Khawaja, MD, MPH,Jose Pacheco, MD,Jeffrey Russell,Joshua K. Sabari, MD,Jenna Zhang,Meredith Little,Kevin Moynihan,Kathleen Dorris,Mohamad Adham Salkeni

A phase 1/1b first-in-human study is evaluating the CNS-penetrant selective ERBB2 inhibitor CGT4255 across multiple tumor types, including HER2-positive breast cancer with brain metastases.

Latest Updated Articles